Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.65 |
| ▸ | CTSS | P25774 | 1/20 | 0.65 |
| ▸ | CTSK | P43235 | 1/20 | 0.65 |
| ▸ | CCKBR | P32239 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | KLK7 | P49862 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NMBR | P28336 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371623 | 0.93 | NMBR (0.64) | CTSLCTSSCTSKCCKBRTACR1 | |
| SCHEMBL4214126 | 0.89 | CTSL (0.69) | CTSLCTSSCTSKCCKBRMAPT | |
| SCHEMBL9834534 | 0.87 | CTSL (0.80) | CTSLCTSSCTSKCCKBRMAPT | |
| SCHEMBL12371604 | 0.86 | CTSS (0.60) | CTSLCTSSCTSKACEKLK5 | |
| SCHEMBL20509877 | 0.86 | NMBR (0.69) | CTSLCTSSCTSKMAPTTACR1 | |
| SCHEMBL21954242 | 0.86 | NMBR (0.69) | CTSLCTSSCTSKMAPTTACR1 | |
| SCHEMBL21954243 | 0.86 | NMBR (0.69) | CTSLCTSSCTSKMAPTTACR1 | |
| SCHEMBL30492977 | 0.86 | NMBR (0.69) | CTSLCTSSCTSKMAPTTACR1 | |
| SCHEMBL29194048 | 0.85 | MAPT (0.67) | CTSLCTSSCTSKCCKBRMAPT | |
| SCHEMBL30466625 | 0.85 | MAPT (0.67) | CTSLCTSSCTSKCCKBRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-08-25 | — | — | US | disclosed |
| WO-2009136997-A2 | INHIBITORS OF HUMAN CATHEPSIN L, CATHEPSIN B, AND CATHEPSIN S | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | CTSB, CTSS, CTSV | CTSL 7/4885CTSS 2/4885CTSK 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.